Erlotinib With or Without Bevacizumab in Treating Patients With Stage IV Non-Small Cell Lung Cancer With EGFR Mutations
by on Tuesday, February 14th, 2012 | No Comments
Condition: Stage IV Non-small Cell Lung Cancer
Interventions: Drug: erlotinib; Biological: bevacizumab; Other: laboratory biomarker analysis
Sponsor: Academic and Community Cancer Research United
Not yet recruiting – verified February 2012
Originally posted here: Erlotinib With or Without Bevacizumab in Treating Patients With Stage IV Non-Small Cell Lung Cancer With EGFR Mutations